

Critical Considerations in Vascular Device-Based Delivery of Cell Therapies

Maria Palasis, Ph.D.
Director, Bioengineering
Boston Scientific Corporation

Cardiomyocyte loss resulting from an acute myocardial infarction (MI) is a leading cause of heart failure and death. Since cardiomyocytes are unable to regenerate an infarcted area, the infarcted tissue heals through the formation of a fibrous scar, often leading to myocardial dysfunction. Cell therapy is currently being used clinically to treat patients post MI. However, little is known regarding the optimal delivery methods for cell therapies. This presentation will review different approaches for myocardial cell delivery including the strategic considerations important for the development of the combination product.